|Day Low/High||4.41 / 4.65|
|52 Wk Low/High||3.72 / 9.48|
The growth of laser eye surgery in emerging markets offers huge opportunities for Iridex, says the company's CFO James Mackaness.
Upgrades: ALJ, APWC, EXH, GTN.A, HCOM, LIWA, MOBI, OSTK, SWFT, TMS, VOC Downgrades: ACU, ADK, AXR, BRP, BXE, CAP, CITZ, CLMS, CRWN, CTIB, CVTI, DAVE, DYNT, EDGW, EMMS, ESTE, HTCO, IRIX, LMIA, LNBB, MASC, MCBI, MHH, MOC, NBBC, NOVB, NWPX, PMBC, PNRG, PZZI, RBCAA, RCKY, STRN, SYNL, TOWR, TWIN, UBCP, UMPQ, USAP, WLFC Initiations: AQ, IMMY Read on to get TheStreet Quant Ratings' detailed report:
All it takes is one big drug approval, a buyout from big pharma or a plump contract from a major provider to send shares of penny stocks like these soaring.
Health stocks such as Adolor and Advancis Pharmaceutical lead small-cap movers.
Hopes are high that regulators will approve the company's vision treatment in December.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.